Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 548

1.

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.

Vermeire S, D'heygere F, Nakad A, Franchimont D, Fontaine F, Louis E, Van Hootegem P, Dewit O, Lambrecht G, Strubbe B, Baert F.

Patient Prefer Adherence. 2018 Jul 6;12:1193-1202. doi: 10.2147/PPA.S154181. eCollection 2018.

2.

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, Ferrante M.

Gut. 2018 Jul 14. pii: gutjnl-2018-316845. doi: 10.1136/gutjnl-2018-316845. [Epub ahead of print] No abstract available.

PMID:
30007919
3.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M.

Aliment Pharmacol Ther. 2018 Aug;48(3):388-389. doi: 10.1111/apt.14855. No abstract available.

4.

VIEWPOINT: Defining endoscopic remission in ileocolonic Crohn's disease: let's start from scratch.

Bossuyt P, Louis E, Mary JY, Vermeire S, Bouhnik Y.

J Crohns Colitis. 2018 Jul 6. doi: 10.1093/ecco-jcc/jjy097. [Epub ahead of print]

PMID:
29982528
5.

Inherited p40phox deficiency differs from classic chronic granulomatous disease.

van de Geer A, Nieto-Patlán A, Kuhns DB, Tool AT, Arias AA, Bouaziz M, de Boer M, Franco JL, Gazendam RP, van Hamme JL, van Houdt M, van Leeuwen K, Verkuijlen PJ, van den Berg TK, Alzate JF, Arango-Franco CA, Batura V, Bernasconi AR, Boardman B, Booth C, Burns SO, Cabarcas F, Cerf Bensussan N, Charbit-Henrion F, Corveleyn A, Deswarte C, Esnaola Azcoiti M, Foell D, Gallin JI, Garcés C, Guedes M, Hinze CH, Holland SM, Hughes SM, Ibañez P, Malech HL, Meyts I, Moncada-Velez M, Moriya K, Neves E, Oleastro M, Perez L, Rattina V, Oleaga-Quintas C, Warner N, Muise AM, Serafin López J, Trindade E, Vasconselos J, Vermeire S, Wittkowski H, Worth A, Abel L, Dinauer MC, Arkwright PD, Roos D, Casanova JL, Kuijpers TW, Bustamante J.

J Clin Invest. 2018 Jul 3. pii: 97116. doi: 10.1172/JCI97116. [Epub ahead of print]

6.

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.

Momozawa Y, Dmitrieva J, Théâtre E, Deffontaine V, Rahmouni S, Charloteaux B, Crins F, Docampo E, Elansary M, Gori AS, Lecut C, Mariman R, Mni M, Oury C, Altukhov I, Alexeev D, Aulchenko Y, Amininejad L, Bouma G, Hoentjen F, Löwenberg M, Oldenburg B, Pierik MJ, Vander Meulen-de Jong AE, Janneke van der Woude C, Visschedijk MC; International IBD Genetics Consortium, Lathrop M, Hugot JP, Weersma RK, De Vos M, Franchimont D, Vermeire S, Kubo M, Louis E, Georges M.

Nat Commun. 2018 Jun 21;9(1):2427. doi: 10.1038/s41467-018-04365-8.

7.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group.

J Crohns Colitis. 2018 Jun 15. doi: 10.1093/ecco-jcc/jjy085. [Epub ahead of print]

PMID:
29917064
8.

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.

Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C.

Inflamm Bowel Dis. 2018 May 30. doi: 10.1093/ibd/izy131. [Epub ahead of print]

PMID:
29850873
9.

Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation.

Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, López-Sanromán A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

J Crohns Colitis. 2018 May 18. doi: 10.1093/ecco-jcc/jjy069. [Epub ahead of print]

PMID:
29788233
10.

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, Ferrante M, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD).

United European Gastroenterol J. 2018 Apr;6(3):439-445. doi: 10.1177/2050640617722310. Epub 2017 Jul 26.

11.

Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey.

Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, DiBonaventura M.

J Crohns Colitis. 2018 Apr 27;12(5):600-609. doi: 10.1093/ecco-jcc/jjy024.

PMID:
29718244
12.

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2018 Apr 25. pii: S1542-3565(18)30402-6. doi: 10.1016/j.cgh.2018.04.040. [Epub ahead of print]

PMID:
29704680
13.

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.

Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.

Gastroenterology. 2018 Jul;155(1):76-87. doi: 10.1053/j.gastro.2018.03.032. Epub 2018 Mar 28.

PMID:
29601825
14.

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).

Franchimont D, Ferrante M, Louis E, De Vos M, Dewit O, Van Hootegem P, Moreels T, Liefferinckx C, Bossuyt P, Baert F, Rahier JF, Vermeire S.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):49-53. No abstract available.

PMID:
29562378
15.

New treatment options for inflammatory bowel diseases.

Verstockt B, Ferrante M, Vermeire S, Van Assche G.

J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. Review.

16.

Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease.

Amininejad L, Charloteaux B, Theatre E, Liefferinckx C, Dmitrieva J, Hayard P, Muls V, Maisin JM, Schapira M, Ghislain JM, Closset P, Talib M, Abramowicz M, Momozawa Y, Deffontaine V, Crins F, Mni M, Karim L, Cambisano N, Ornemese S, Zucchi A, Minsart C, Deviere J, Hugot JP, De Vos M, Louis E, Vermeire S, Van Gossum A, Coppieters W, Twizere JC, Georges M, Franchimont D; International IBD Genetics Consortium.

Gastroenterology. 2018 Jun;154(8):2165-2177. doi: 10.1053/j.gastro.2018.02.028. Epub 2018 Mar 6.

PMID:
29501442
17.

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.

Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S.

Eur J Gastroenterol Hepatol. 2018 May;30(5):539-545. doi: 10.1097/MEG.0000000000001091.

PMID:
29462028
18.

Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.

Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club.

J Crohns Colitis. 2018 Apr 27;12(5):517-524. doi: 10.1093/ecco-jcc/jjy014.

PMID:
29401297
19.

Immunogenicity of biologics in inflammatory bowel disease.

Vermeire S, Gils A, Accossato P, Lula S, Marren A.

Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355. eCollection 2018.

20.

Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.

Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2018 Mar;47(6):773-783. doi: 10.1111/apt.14514. Epub 2018 Jan 19.

PMID:
29349829
21.

Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT.

Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M, Lindsay JO, Onida F, Salas A, Saccardi R, Vermeire S, Rovira M, Ricart E; European Crohn’s and Colitis Organisation (ECCO); European Society for Blood and Marrow Transplantation (EBMT); Autoimmune Diseases Working Party (ADWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE).

J Crohns Colitis. 2018 Mar 28;12(4):476-488. doi: 10.1093/ecco-jcc/jjx184.

PMID:
29325112
22.

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID.

Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6.

PMID:
29317275
23.

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).

Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S.

Gut. 2017 Dec 15. pii: gutjnl-2017-314562. doi: 10.1136/gutjnl-2017-314562. [Epub ahead of print]

24.

Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology.

Noben M, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, Ferrante M.

United European Gastroenterol J. 2017 Dec;5(8):1073-1081. doi: 10.1177/2050640617722903. Epub 2017 Jul 21. Review.

25.

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A.

Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11.

PMID:
29226370
26.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2018 Mar 28;12(4):408-418. doi: 10.1093/ecco-jcc/jjx161.

PMID:
29216349
27.

Mucosal Healing and Long-Term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2017 Dec 1. pii: S1542-3565(17)31419-2. doi: 10.1016/j.cgh.2017.11.046. [Epub ahead of print]

PMID:
29203225
28.

Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.

van Hoeve K, Hoffman I, Vermeire S.

Expert Opin Drug Saf. 2018 Feb;17(2):185-196. doi: 10.1080/14740338.2018.1413090. Epub 2017 Dec 10. Review.

PMID:
29202588
29.

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ.

Aliment Pharmacol Ther. 2018 Jan;47(2):229-237. doi: 10.1111/apt.14421. Epub 2017 Nov 21.

30.

Quantitative microbiome profiling links gut community variation to microbial load.

Vandeputte D, Kathagen G, D'hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito RY, De Commer L, Darzi Y, Vermeire S, Falony G, Raes J.

Nature. 2017 Nov 23;551(7681):507-511. doi: 10.1038/nature24460. Epub 2017 Nov 15.

PMID:
29143816
31.

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A.

Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255.

PMID:
29140943
32.

NOD2 and bacterial recognition as therapeutic targets for Crohn's disease.

de Bruyn M, Vermeire S.

Expert Opin Ther Targets. 2017 Dec;21(12):1123-1139. doi: 10.1080/14728222.2017.1397627. Epub 2017 Nov 2. Review.

PMID:
29096557
33.

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study.

Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N.

Clin Transl Gastroenterol. 2017 Nov 2;8(11):e126. doi: 10.1038/ctg.2017.52.

34.

Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice.

Germain A, de Buck van Overstraeten A, Wolthuis A, Ferrante M, Vermeire S, Van Assche G, D'Hoore A.

Colorectal Dis. 2018 Feb;20(2):O30-O38. doi: 10.1111/codi.13948.

PMID:
29091335
35.

Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC.

Conceição-Neto N, Deboutte W, Dierckx T, Machiels K, Wang J, Yinda KC, Maes P, Van Ranst M, Joossens M, Raes J, Vermeire S, Matthijnssens J.

Gut. 2018 Aug;67(8):1558-1559. doi: 10.1136/gutjnl-2017-315281. Epub 2017 Oct 24. No abstract available.

36.

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease.

Vanhove W, Nys K, Arijs I, Cleynen I, Noben M, De Schepper S, Van Assche G, Ferrante M, Vermeire S.

J Crohns Colitis. 2018 Jan 24;12(2):178-187. doi: 10.1093/ecco-jcc/jjx122.

PMID:
29029005
37.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.

38.

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.

Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D'Hoore A.

J Crohns Colitis. 2017 Oct 27;11(11):1353-1361. doi: 10.1093/ecco-jcc/jjx095.

PMID:
28981886
39.

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.

Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S.

J Crohns Colitis. 2018 Jan 5;12(1):32-38. doi: 10.1093/ecco-jcc/jjx110.

PMID:
28981768
40.

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.

D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O.

J Crohns Colitis. 2018 Jan 24;12(2):188-196. doi: 10.1093/ecco-jcc/jjx128.

41.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

PMID:
28885228
42.

Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.

Boland BS, Vermeire S.

Gastroenterol Clin North Am. 2017 Sep;46(3):627-644. doi: 10.1016/j.gtc.2017.05.015. Review.

PMID:
28838419
43.

PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis.

Mahler M, Damoiseaux J, Ballet V, Dillaerts D, Bentow C, Cohen Tervaert JW, Blockmans D, Boeckxstaens G, Aguilera-Lizarraga J, Csernok E, Vermeire S, Bossuyt X.

Clin Chem Lab Med. 2017 Nov 27;56(1):e27-e30. doi: 10.1515/cclm-2017-0346. No abstract available.

PMID:
28755529
44.

Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres.

de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A.

Br J Surg. 2017 Nov;104(12):1713-1722. doi: 10.1002/bjs.10595. Epub 2017 Jul 26.

PMID:
28745410
45.

Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease.

Bian S, Lu J, Delport F, Vermeire S, Spasic D, Lammertyn J, Gils A.

Drug Test Anal. 2018 Mar;10(3):592-596. doi: 10.1002/dta.2250. Epub 2017 Aug 23.

PMID:
28743169
46.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2018 Jun;67(6):1087-1094. doi: 10.1136/gutjnl-2016-313213. Epub 2017 Jul 11.

PMID:
28698230
47.

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).

Wauters L, Smets F, De Greef E, Bontems P, Hoffman I, Hauser B, Alliet P, Arts W, Peeters H, Van Biervliet S, Paquot I, Van de Vijver E, De Vos M, Bossuyt P, Rahier JF, Dewit O, Moreels T, Franchimont D, Muls V, Fontaine F, Louis E, Coche JC, Baert F, Paul J, Vermeire S, Veereman G.

Inflamm Bowel Dis. 2017 Sep;23(9):1584-1591. doi: 10.1097/MIB.0000000000001193.

PMID:
28696956
48.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC.

Nature. 2017 Jul 13;547(7662):173-178. doi: 10.1038/nature22969. Epub 2017 Jun 28.

49.

The intestinal barrier: a fundamental role in health and disease.

Vancamelbeke M, Vermeire S.

Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834. doi: 10.1080/17474124.2017.1343143. Epub 2017 Jun 26. Review.

PMID:
28650209
50.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.

Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16.

PMID:
28622097

Supplemental Content

Loading ...
Support Center